Incyte (NASDAQ: INCY)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Incyte Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Incyte Company Info
Incyte isn't the only drugmaker with a JAK inhibitor, but Jakafi's differentiation as a JAK1 and JAK2 inhibitor has helped the company stay on top of the treatment paradigm for myelofibrosis.
News & Analysis
Billionaire investors are backing up their trucks and loading up on these stocks.
Don't overlook these two promising companies.
Find out what held these laggards back.
There's definitely already a crowded market for PD-1 and PD-L1 immunotherapies.
Drugmakers can be excellent long-term holdings.
Incyte is betting bigger on ruxolitinib to bring back growth.
Several products contributed to the biotech's solid growth.
Investors should take notice of this four-way competition.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 01/30/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Podcast Episodes
A number of companies suffered setbacks this year.
Checkpoint inhibitors remain top sellers, but it wasn’t all rosy news this year.
Earnings Transcripts
INCY earnings call for the period ending September 30, 2021.
INCY earnings call for the period ending June 30, 2021.
INCY earnings call for the period ending March 31, 2021.
INCY earnings call for the period ending February 9, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.